Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer.
Meflin
cancer-associated fibroblasts
immunoglobulin superfamily containing leucine-rich repeat
matrix remodeling-associated protein 8
pancreatic cancer
tumor microenvironment
Journal
Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
13
08
2021
accepted:
11
12
2021
pubmed:
13
1
2022
medline:
30
3
2022
entrez:
12
1
2022
Statut:
ppublish
Résumé
Cancer-associated fibroblasts (CAFs), a compartment of the tumor microenvironment, were previously thought to be a uniform cell population that promotes cancer progression. However, recent studies have shown that CAFs are heterogeneous and that there are at least two types of CAFs, that is, cancer-promoting and -restraining CAFs. We previously identified Meflin as a candidate marker of cancer-restraining CAFs (rCAFs) in pancreatic ductal adenocarcinoma (PDAC). The precise nature of rCAFs, however, has remained elusive owing to a lack of understanding of their comprehensive gene signatures. Here, we screened genes whose expression correlated with Meflin in single-cell transcriptomic analyses of human cancers. Among the identified genes, we identified matrix remodeling-associated protein 8 (MXRA8), which encodes a type I transmembrane protein with unknown molecular function. Analysis of MXRA8 expression in human PDAC samples showed that MXRA8 was differentially co-expressed with other CAF markers. Moreover, in patients with PDAC or syngeneic tumors developed in MXRA8-knockout mice, MXRA8 expression did not affect the roles of CAFs in cancer progression, and the biological importance of MXRA8
Identifiants
pubmed: 35020975
doi: 10.1111/pin.13198
pmc: PMC9305816
doi:
Substances chimiques
Biomarkers
0
Immunoglobulins
0
Membrane Proteins
0
Mxra8 protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-175Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 20gm0810007h0105
Organisme : Japan Agency for Medical Research and Development
ID : 20gm1210009s0102
Organisme : Japan Society for the Promotion of Science
ID : 18H02638
Organisme : Japan Society for the Promotion of Science
ID : 20H03467
Informations de copyright
© 2022 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
Références
Nat Commun. 2019 Feb 27;10(1):963
pubmed: 30814501
Nature. 2004 Nov 18;432(7015):332-7
pubmed: 15549095
Trends Cancer. 2019 Nov;5(11):724-741
pubmed: 31735290
PLoS One. 2021 Mar 24;16(3):e0248267
pubmed: 33760832
Front Cell Dev Biol. 2021 Oct 05;9:749924
pubmed: 34676218
Glia. 2003 Dec;44(3):190-204
pubmed: 14603461
Cancer Sci. 2020 Apr;111(4):1047-1057
pubmed: 32060987
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Nature. 2018 May;557(7706):570-574
pubmed: 29769725
Nat Commun. 2018 Dec 4;9(1):5150
pubmed: 30514914
Cancer Discov. 2019 Feb;9(2):282-301
pubmed: 30366930
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Oncol Rep. 2020 Sep;44(3):838-848
pubmed: 32705221
Pancreas. 2002 Aug;25(2):e30-5
pubmed: 12142752
J Exp Med. 2014 Jul 28;211(8):1503-23
pubmed: 25071162
Genes Cells. 2021 Jul;26(7):495-512
pubmed: 33960573
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Gut. 2019 Jan;68(1):159-171
pubmed: 30177543
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
Cell Stem Cell. 2017 Feb 2;20(2):261-273.e3
pubmed: 27867035
Prostate. 2020 Feb;80(2):173-185
pubmed: 31763714
Cold Spring Harb Perspect Biol. 2020 Dec 1;12(12):
pubmed: 32179507
Cancer Discov. 2019 Aug;9(8):1102-1123
pubmed: 31197017
Nat Genet. 2020 Jun;52(6):594-603
pubmed: 32451460
Sci Rep. 2016 Feb 29;6:22288
pubmed: 26924503
Nat Commun. 2020 May 8;11(1):2285
pubmed: 32385277
Nat Commun. 2021 May 5;12(1):2540
pubmed: 33953163
Cell. 2015 Jan 15;160(1-2):324-38
pubmed: 25557080
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
EMBO J. 2021 Jun 1;40(11):e107333
pubmed: 33950524
Immunity. 2020 Jul 14;53(1):187-203.e8
pubmed: 32640259
Cell. 2019 Jun 13;177(7):1714-1724.e12
pubmed: 31080063
Circ Res. 2019 Aug 2;125(4):414-430
pubmed: 31221024
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):282-295
pubmed: 30778141
Cancer Discov. 2020 Feb;10(2):232-253
pubmed: 31699795
FEBS J. 2022 May;289(9):2429-2447
pubmed: 33786982
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Nat Genet. 2017 May;49(5):708-718
pubmed: 28319088
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):186-196
pubmed: 26278673
Gastroenterology. 2021 Mar;160(4):1224-1239.e30
pubmed: 33197448
Ann Rheum Dis. 2019 Oct;78(10):1379-1387
pubmed: 31405848
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
J Clin Invest. 2017 Mar 1;127(3):737-749
pubmed: 28248203
Am J Physiol Lung Cell Mol Physiol. 2019 May 1;316(5):L872-L885
pubmed: 30675802
Cell Res. 2019 Sep;29(9):725-738
pubmed: 31273297
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
Cell. 2014 Sep 25;159(1):80-93
pubmed: 25259922
Int J Cancer. 2012 Dec 1;131(11):2499-508
pubmed: 22447203
Nature. 2021 May;593(7860):575-579
pubmed: 33981032
J Bone Miner Res. 2012 Sep;27(9):2024-34
pubmed: 22492581
Gastroenterology. 2013 Jun;144(6):1210-9
pubmed: 23622130
Pathol Int. 2022 Mar;72(3):161-175
pubmed: 35020975
Br J Cancer. 2014 Nov 11;111(10):1917-23
pubmed: 25314063
Nature. 2018 Oct;562(7727):367-372
pubmed: 30283141
Gut. 2015 Sep;64(9):1476-84
pubmed: 25994217
EMBO J. 2020 Apr 1;39(7):e103255
pubmed: 32128839
J Cell Physiol. 2008 Sep;216(3):603-14
pubmed: 18366072
Eur Respir J. 2021 Dec 23;58(6):
pubmed: 34049947
Cancer Res. 2019 Oct 15;79(20):5367-5381
pubmed: 31439548